Title
Safety and Efficacy Study of Umbilical Mesenchymal Stem Cells for Liver Cirrhosis
Clinical Trial of Umbilical Mesenchymal Stem Cells Transplantation for Liver Cirrhosis-Phase I/II
Phase
Phase 1/Phase 2Study Type
InterventionalStatus
Unknown statusIndication/Condition
Liver CirrhosisIntervention/Treatment
autologous mesenchymal stem cells ...Study Participants
320Liver cirrhosis and subsequent liver failure are leading causes of morbidity and mortality worldwide. Alcohol abuse and viral hepatitis are the most common causes of cirrhosis. Novel therapies are necessary to prevent or block the process of the disease. In this current prospective cohort, the investigators plan to organize four hospitals to determine the safety and efficacy of intravenous administration of umbilical mesenchymal stem cells in the treatment of patients with liver cirrhosis in next three years.
Conventional therapy plus UC-MSC intravenous administration (4x107/40ml, once per three months, four times in one year)
Conventional therapy without cell therapy
only apply for conventional medical therapy without any cell therapy
combination of conventional therapy with umbilical mesenchymal stem cells intravenous injection, (4x107/40ml, once per three months, four times in one year)
Inclusion Criteria: written informed consent aged 30-60 years clinical diagnosis of compensated or decompensated liver child-Pugh B/C (7-12 points) expecting lifetime is over three years Exclusion Criteria: pregnant woman patient with severe vascular diseases patient with any organ failure patient with any tumors patient with HIV patient who has been transplanted patient treated with immunosuppressors patient for whom the follow-up is considered impossible patients with any disease or condition which the investigator or treating physician feels would interfere with the trial or the safety of the subject
